Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650
This study is recruiting at 14 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes Mellitus
- T2DM
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Desert Clinical Research · Mesa, AZ
Florida · 3
- Accel Research Sites - DeLand · DeLand, FL
- Charter Research · Orlando, FL
- K2 Medical Research The Villages LLC · The Villages, FL
Georgia · 1
- Centricity Research IRT - DBA IACT Health Columbus Piedmont · Columbus, GA
Indiana · 1
- The South Bend Clinic · South Bend, IN
Missouri · 2
- Jefferson City Medical Center · Jefferson City, MO
- Clay Platte Family Medicine · Kansas City, MO
Nebraska · 1
- Methodist Physicians Clinic · Fremont, NE
Nevada · 1
- Santa Rosa Medical Centers of Nevada · Las Vegas, NV
North Carolina · 1
- Lucas Research, Inc. · Morehead City, NC
Ohio · 1
- Centricity Research Columbus · Columbus, OH
Utah · 1
- Olympus Family Medicine · Salt Lake City, UT
Virginia · 1
- Manassas Clinical Research Center · Manassas, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.